Trials / Recruiting
RecruitingNCT05866627
A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants
A Phase 1 Open-label, 2-Part Crossover Study to Assess the Effect of Acid-reducing Agent Famotidine on the Pharmacokinetics of Afimetoran (BMS-986256) in Healthy Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 76 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to confirm there is no significant effect of gastric pH changes of famotidine on the drug levels of afimetoran in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famotidine | Specified dose on specified days |
| DRUG | Afimetoran | Specified dose on specified days |
Timeline
- Start date
- 2023-07-04
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
- First posted
- 2023-05-19
- Last updated
- 2025-01-22
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05866627. Inclusion in this directory is not an endorsement.